Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic Review
DOI: https://doi.org/10.2147/TCRM.S414460
2023-06-24
Therapeutics and Clinical Risk Management
Abstract:Hanqing Liu, 1, &ast Man Lu, 1, &ast Jiawei Hu, 1 Guangzhao Fu, 2 Qinyu Feng, 3 Shengrong Sun, 1 Chuang Chen 1 1 Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China; 2 Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China; 3 Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chuang Chen; Shengrong Sun, Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan University, Jiefang Road 238, Wuhan, 430060, People's Republic of China, Tel/Fax +86 27 88041911, Email ; Purpose: Levothyroxine is a common prescribed drug. Many medications and food, however, can interfere with its bioavailability. The aim of this review was to summarize the medications, food and beverages that interact with levothyroxine and to assess their effects, mechanisms and treatments. Methods: A systematic review on interfering substances that interact with levothyroxine was performed. Web of Science, Embase, PubMed, the Cochrane library, grey literature from other sources and the lists of references were searched for human studies comparing the levothyroxine efficacy with and without interfering substances. The patient characteristics, drug classes, effects and mechanism were extracted. The NHLBI study quality assessment tools and the JBI critical appraisal checklist were used to assess the quality of included studies. Results: A total of 107 articles with 128 studies were included. Drugs interactions were revealed in calcium and iron supplements, proton pump inhibitors, bile acid sequestrants, phosphate binders, sex hormones, anticonvulsants and other drugs. Some food and beverage could also induce malabsorption. Proposed mechanisms included direct complexing, alkalization, alteration of serum thyroxine-binding globulin levels and acceleration of levothyroxine catabolism via deiodination. Dose adjustment, administration separation and discontinuation of interfering substances can eliminate the interactions. Liquid solutions and soft-gel capsules could eliminate the malabsorption due to chelation and alkalization. The qualities of most included studies were moderate. Conclusion: Lots of medications and food can impair the bioavailability of levothyroxine. Clinicians, patients and pharmaceutical companies should be aware of the possible interactions. Further well-designed studies are needed to provide more solid evidence on treatment and mechanisms. Keywords: L-T4, drug, interference, malabsorption, side effect, solution Levothyroxine (LT4) is among the most prescribed medications in the world and the mainstay treatment for hypothyroidism. 1,2 Generally, a 1.6–1.8 μg/kg/d of oral LT4 is recommended to be ingested on empty stomach early in the morning. Although it is cost-saving, easy-to-take and has many other advantages, its bioavailability has been reported to be altered by lots of medications. The interference can elevate thyrotropin (TSH) and even decrease triiodothyronine (T3) and thyroxine (T4) despite dose elevation (>1.9 μg/kg/d). A retrospective population analysis based on a local database in the UK revealed that 58.9% of LT4-treated patients were concurrently taking ≥1 drug for other medical conditions. 3 The most frequently prescribed concomitant drugs were statins (17.6%), proton pump inhibitors (PPIs) (13.6%), and calcium supplements (6.8%). Another database study in Colombia revealed a similar result. 4 A percentage of 68.5% of LT4-treated patients took other drugs. The spectrum of concurrent agents was somewhat different from the study in the UK, which may be explained by the differences in the spectrum of diseases and prescription preference. The antiulcer agents (44%) were the leading concurrently taking ones, followed by hypoglycemics (17.4%), and iron supplements (16.1%). Though the majority of patients with co-ingestion were asymptomatic and received constant doses of LT4, it would be up to 12–15% of total LT4-treated patients suffering unsuppressed TSH if 1 in 5 had drug interactions. Besides, some food and beverages could also impair the absorption of oral LT4. Since the concomitant intake of food or certain drugs can either directly bind with LT4 or impair its solubility, a 0.5–2 hours dosing gap is generally required for the empty of stomach. 5 The LT4 liquid preparation intrinsically avoid dissolution and can recover impaired bioavailability due to concomitant intake. Th -Abstract Truncated-
health care sciences & services